Literature DB >> 9519743

13C/31P NMR studies on the mechanism of insulin resistance in obesity.

K F Petersen1, R Hendler, T Price, G Perseghin, D L Rothman, N Held, J M Amatruda, G I Shulman.   

Abstract

The mechanism of insulin resistance in obesity was examined in ten obese (BMI 33 +/- 1 kg/m2) and nine lean (BMI 22 +/- 1 kg/m2) Caucasian women during a hyperglycemic-hyperinsulinemic clamp using 13C and 31P nuclear magnetic resonance (NMR) spectroscopy to measure rates of muscle glycogen synthesis and intramuscular glucose-6-phosphate (G-6-P) concentrations. Under similar steady-state plasma concentrations of glucose (approximately 11 mmol/l) and insulin (approximately 340 pmol/l), rates of muscle glycogen synthesis were reduced approximately 70% in the obese subjects (52 +/- 8 micromol/[l muscle-min]) as compared with the rates in the lean subjects (176 +/- 22 micromol/[l muscle-min]; P < 0.0001). Basal concentrations of intramuscular G-6-P were similar in the obese and lean subjects; but during the clamp, G-6-P failed to increase in the obese group (deltaG-6-P obese 0.044 +/- 0.011 vs. lean 0.117 +/- 0.011 mmol/l muscle; P < 0.001), reflecting decreased muscle glucose transport and/or phosphorylation activity. We conclude that insulin resistance in obesity can be mostly attributed to impairment of insulin-stimulated muscle glycogen synthesis due to a defect in glucose transport and/or phosphorylation activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9519743     DOI: 10.2337/diabetes.47.3.381

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  27 in total

Review 1.  Cellular mechanisms of insulin resistance.

Authors:  G I Shulman
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

2.  Protein phosphorylation can regulate metabolite concentrations rather than control flux: the example of glycogen synthase.

Authors:  James R A Schafer; David A Fell; Douglas Rothman; Robert G Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

Review 3.  The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome.

Authors:  François R Jornayvaz; Varman T Samuel; Gerald I Shulman
Journal:  Annu Rev Nutr       Date:  2010-08-21       Impact factor: 11.848

4.  Pathogenesis of selective insulin resistance in isolated hepatocytes.

Authors:  Joshua R Cook; Fanny Langlet; Yoshiaki Kido; Domenico Accili
Journal:  J Biol Chem       Date:  2015-04-14       Impact factor: 5.157

Review 5.  Pediatric endocrine disorders of energy balance.

Authors:  Robert H Lustig
Journal:  Rev Endocr Metab Disord       Date:  2005-12       Impact factor: 6.514

6.  Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4.

Authors:  J K Kim; A Zisman; J J Fillmore; O D Peroni; K Kotani; P Perret; H Zong; J Dong; C R Kahn; B B Kahn; G I Shulman
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

7.  The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome.

Authors:  Kitt Falk Petersen; Sylvie Dufour; David B Savage; Stefan Bilz; Gina Solomon; Shin Yonemitsu; Gary W Cline; Douglas Befroy; Laura Zemany; Barbara B Kahn; Xenophon Papademetris; Douglas L Rothman; Gerald I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-18       Impact factor: 11.205

Review 8.  New insights into the pathogenesis of insulin resistance in humans using magnetic resonance spectroscopy.

Authors:  Kitt Falk Petersen; Gerald I Shulman
Journal:  Obesity (Silver Spring)       Date:  2006-02       Impact factor: 5.002

Review 9.  Mitochondrial dysfunction and type 2 diabetes.

Authors:  Rebecca Parish; Kitt Falk Petersen
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

Review 10.  The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux.

Authors:  Varman T Samuel; Gerald I Shulman
Journal:  J Clin Invest       Date:  2016-01-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.